Abstract
From the rat C6 glioma cell line in culture, we selected camptothecin-resistant variants by growth in the presence of increasing amounts of this drug (C6CPT10, C6CPT50 and C6CPT100, growing respectively with 10, 50 and 100 ng ml–1 camptothecin). The degree of resistance to camptothecin ranged between 15-fold (C6CPT10) and 30-fold (C6CPT50and C6CPT100). The C6CPT10 cell line presented a collateral sensitivity to etoposide (3.6-fold), while the C6CPT50 and C6CPT100 cell lines were cross-resistant to etoposide (1.8-fold) The resistant lines were characterised by a two-fold reduced content and catalytic activity of topoisomerase I, and C6CPT50 and C6CPT100 presented a significant increase in topoisomerase IIα content and catalytic activity and a marked overexpression of P-glycoprotein. We explored the cytotoxicity of combinations of a topoisomerase I inhibitor (camptothecin) and a topoisomerase II inhibitor (doxorubicin or etoposide) at several molar ratios, allowing the evaluation of their synergistic or antagonistic effects on cell survival using the median effect principle. The simultaneous combination of camptothecin and doxorubicin or etoposide was additive or antagonistic in C6 cells, slightly synergistic in the C6CPT10 line and never more than additive in the C6CPT50 and C6CPT100 cell lines. The sequential combination of doxorubicin and camptothecin gave additivity in the order camptothecin → doxorubicin and antagonism in the order doxorubicin → camptothecin. Clinical protocols combining a topoisomerase I and a topoisomerase II inhibitor should be considered with caution because antagonistic effects have been observed with combinations of camptothecin and doxorubicin. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andersen AH, Svejstrup JQ and Westergaard O (1994) The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II. Adv Pharmacol 29A: 83–101
Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Kurata T, Ohmatsu H, Kubota K, Sekine I, Hojo N, Matsumoto T, Kodama T, Klakinuma R, Nishiwaki Y and Saijo N (1997) Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small cell lung cancer. Br J Cancer 76: 1494–1499
Andoh T and Okada K (1994) Drug resistance mechanisms of topoisomerase I drugs. Adv Pharmacol 29B: 93–103
Benda P, Lightbody J, Sato G, Levine L and Sweet W (1968) Differentiated rat glial cell strain in tissue culture. Science 161: 370–371
Bertrand R, O'Connor PM, Kerrigan D and Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cell. Eur J Cancer 28: 743–748
Bonner JA and Kozelsky TF (1996) The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 39: 109–112
Chaudhary PM and Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Nat Cancer Inst 85: 632–639
Chen AY, Yu C, Potmesil M, Wall ME, Wani MC and Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039–6044
Chou J and Chou TC (1987) Dose-effect analysis with microcomputers. Biosoft: Cambridge
Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55
Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137–171
Herben VMM, ten Bokkel Huinink WW, Dubbelman AC, Mandjes IAM, Groot Y, van Gortel-van Zomeren DM and Beijnen JH (1997) Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer 76: 1500–1508
Hill BT, Deuchars K, Hosking LK, Ling V and Whelan RDH (1990) Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Nat Cancer Inst 82: 607–612
Huet S, Schott B and Robert J (1992) P-glycoprotein overexpression cannot explain the complete doxorubicin resistance phenotype in rat glioblastoma cell lines. Br J Cancer 65: 538–544
Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129–1136
Kohn KW (1991) Principles and practice of DNA filter elution. Pharmacol Ther 49: 55–77
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685
Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351–375
Liu LF and Miller KG (1981) Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA, 3487–3491
Masumoto N, Nakano S, Esaki T, Tatsumoto T, Fujishima H, Baba E, Nakamura M and Niho Y (1995) Sequence-dependent modulation of anticancer drug activities by 7-ethyl-hydroxy-camptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res 15: 405–410
Montaudon D, Pourquier P, Denois F, de Tinguy-Moreaud E, Lagarde P and Robert J (1997) Differential stabilization of topoisomerase II – DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cell. Eur J Biochem 245: 307–315
Nitiss JL (1994) Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol 29A: 103–134
Oguro M, Seki Y, Okada K and Andoh T (1990) Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother 44: 209–216
Osheroff N, Corbett AH and Robinson MJ (1994) Mechanism of action of topoisomerase II – targeted antineoplastic drugs. Adv Pharmacol 29B: 105–126
Pommier Y, Tanizawa A and Kohn KW (1994) Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 29B: 73–92
Rabier MJ, Bruno NA and Slate DL (1991) Multifactorial resistance in LS174T human colon carcinoma cells selected with doxorubicin. Int J Cancer 49: 601–607
Robert J and Larsen AK (1998) Drug resistance to topoisomerase II inhibitors. Biochimie 80: 247–254
Stahl M and Kasimir-Bauer S Harstrick (1997) Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anticancer Drug 8: 671–676
Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF and Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962–7965
Tan KB, Mattern MR, Eng WK, McCabe FL and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Nat Cancer Inst 81: 1732–1735
Wang JC (1994) DNA topoisomerases as targets of therapeutics. An overview. Adv Pharmacol 29A: 1–19
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pavillard, V., Kherfellah, D., Richard, S. et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br J Cancer 85, 1077–1083 (2001). https://doi.org/10.1054/bjoc.2001.2027
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2027
Keywords
This article is cited by
-
Multifunctional Enveloped Mesoporous Silica Nanoparticles for Subcellular Co-delivery of Drug and Therapeutic Peptide
Scientific Reports (2014)
-
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
Cancer Chemotherapy and Pharmacology (2014)
-
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model
Journal of Materials Science: Materials in Medicine (2010)
-
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines
Leukemia (2002)